Cargando…

Alterations of lipid metabolism in Wilson disease

INTRODUCTION: Wilson disease (WD) is an inherited disorder of human copper metabolism, characterised by accumulation of copper predominantly in the liver and brain, leading to severe hepatic and neurological disease. Interesting findings in animal models of WD (Atp7b(-/- )and LEC rats) showed altere...

Descripción completa

Detalles Bibliográficos
Autores principales: Seessle, Jessica, Gohdes, Annina, Gotthardt, Daniel Nils, Pfeiffenberger, Jan, Eckert, Nicola, Stremmel, Wolfgang, Reuner, Ulrike, Weiss, Karl Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127787/
https://www.ncbi.nlm.nih.gov/pubmed/21595966
http://dx.doi.org/10.1186/1476-511X-10-83
_version_ 1782207371825643520
author Seessle, Jessica
Gohdes, Annina
Gotthardt, Daniel Nils
Pfeiffenberger, Jan
Eckert, Nicola
Stremmel, Wolfgang
Reuner, Ulrike
Weiss, Karl Heinz
author_facet Seessle, Jessica
Gohdes, Annina
Gotthardt, Daniel Nils
Pfeiffenberger, Jan
Eckert, Nicola
Stremmel, Wolfgang
Reuner, Ulrike
Weiss, Karl Heinz
author_sort Seessle, Jessica
collection PubMed
description INTRODUCTION: Wilson disease (WD) is an inherited disorder of human copper metabolism, characterised by accumulation of copper predominantly in the liver and brain, leading to severe hepatic and neurological disease. Interesting findings in animal models of WD (Atp7b(-/- )and LEC rats) showed altered lipid metabolism with a decrease in the amount of triglycerides and cholesterol in the serum. However, serum lipid profile has not been investigated in large human WD patient cohorts to date. PATIENTS AND METHODS: This cohort study involved 251 patients examined at the Heidelberg and Dresden (Germany) University Hospitals. Patients were analysed on routine follow-up examinations for serum lipid profile, including triglycerides, cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL). Data on these parameters at time of diagnosis were retrieved by chart review where available. For statistical testing, patients were subgrouped by sex, manifestation (hepatic, neurological, mixed and asymptomatic) and treatment (D-penicillamine, trientine, zinc or combination). RESULTS: A significant difference in total serum cholesterol was found in patients with hepatic symptoms, which diminished under therapy. No alterations were observed for HDL, LDL and triglycerides. CONCLUSION: Contradictory to previous reports using WD animal models (Atp7b(-/- )and LEC rats), the most obvious alteration in our cohort was a lower serum cholesterol level in hepatic-affected patients, which might be related to liver injury. Our data suggested unimpaired cholesterol metabolism in Wilson disease under therapy, independent of the applied medical treatment.
format Online
Article
Text
id pubmed-3127787
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31277872011-07-01 Alterations of lipid metabolism in Wilson disease Seessle, Jessica Gohdes, Annina Gotthardt, Daniel Nils Pfeiffenberger, Jan Eckert, Nicola Stremmel, Wolfgang Reuner, Ulrike Weiss, Karl Heinz Lipids Health Dis Research INTRODUCTION: Wilson disease (WD) is an inherited disorder of human copper metabolism, characterised by accumulation of copper predominantly in the liver and brain, leading to severe hepatic and neurological disease. Interesting findings in animal models of WD (Atp7b(-/- )and LEC rats) showed altered lipid metabolism with a decrease in the amount of triglycerides and cholesterol in the serum. However, serum lipid profile has not been investigated in large human WD patient cohorts to date. PATIENTS AND METHODS: This cohort study involved 251 patients examined at the Heidelberg and Dresden (Germany) University Hospitals. Patients were analysed on routine follow-up examinations for serum lipid profile, including triglycerides, cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL). Data on these parameters at time of diagnosis were retrieved by chart review where available. For statistical testing, patients were subgrouped by sex, manifestation (hepatic, neurological, mixed and asymptomatic) and treatment (D-penicillamine, trientine, zinc or combination). RESULTS: A significant difference in total serum cholesterol was found in patients with hepatic symptoms, which diminished under therapy. No alterations were observed for HDL, LDL and triglycerides. CONCLUSION: Contradictory to previous reports using WD animal models (Atp7b(-/- )and LEC rats), the most obvious alteration in our cohort was a lower serum cholesterol level in hepatic-affected patients, which might be related to liver injury. Our data suggested unimpaired cholesterol metabolism in Wilson disease under therapy, independent of the applied medical treatment. BioMed Central 2011-05-19 /pmc/articles/PMC3127787/ /pubmed/21595966 http://dx.doi.org/10.1186/1476-511X-10-83 Text en Copyright ©2011 Seessle et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Seessle, Jessica
Gohdes, Annina
Gotthardt, Daniel Nils
Pfeiffenberger, Jan
Eckert, Nicola
Stremmel, Wolfgang
Reuner, Ulrike
Weiss, Karl Heinz
Alterations of lipid metabolism in Wilson disease
title Alterations of lipid metabolism in Wilson disease
title_full Alterations of lipid metabolism in Wilson disease
title_fullStr Alterations of lipid metabolism in Wilson disease
title_full_unstemmed Alterations of lipid metabolism in Wilson disease
title_short Alterations of lipid metabolism in Wilson disease
title_sort alterations of lipid metabolism in wilson disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127787/
https://www.ncbi.nlm.nih.gov/pubmed/21595966
http://dx.doi.org/10.1186/1476-511X-10-83
work_keys_str_mv AT seesslejessica alterationsoflipidmetabolisminwilsondisease
AT gohdesannina alterationsoflipidmetabolisminwilsondisease
AT gotthardtdanielnils alterationsoflipidmetabolisminwilsondisease
AT pfeiffenbergerjan alterationsoflipidmetabolisminwilsondisease
AT eckertnicola alterationsoflipidmetabolisminwilsondisease
AT stremmelwolfgang alterationsoflipidmetabolisminwilsondisease
AT reunerulrike alterationsoflipidmetabolisminwilsondisease
AT weisskarlheinz alterationsoflipidmetabolisminwilsondisease